Numerous factors have been reported to influence the pathogenesis of atherosclerosis. The angiotensin I converting enzyme (ACE) gene is a candidate gene for atheroscleroticrelated disease. In the present study, the association between the polymorphism of the ACE gene and peripheral arterial occlusive disease (PAOD) was investigated. Using polymerase chain reaction techniques, 100 patients (age 66.7 AE 7.7 years) with PAOD and 100 age-matched controls were divided into the three ACE genotypes: II, ID and DD (Insertion I and Deletion D). There was no evidence of any association between ACE gene polymorphism and the presence of PAOD (odds ratio 0.759; 95% confidence interval 0.418À1.377). These results indicate an absence of association between DD genotype and PAOD. Further evaluation in a larger population study is required to examine the possibility of an increased risk of PAOD in DD homozygotes.
Introduction
The structure and function of a normal healthy vessel wall are dependent on the balance of several counteracting factors, i.e. vasoconstricting versus vasodilating, growthpromoting versus growth-inhibiting, and proapoptotic versus antiapoptotic. However, under pathophysiologic conditions this balance is upset, leading in the development of vascular hypertrophy and the generation of vascular lesions. For example, during the initiation and progression of atherosclerosis, there is an imbalance in a number of these processes, resulting in a proatherogenic state.
The renin-angiotensin system (RAS), one of the oldest known hormone systems, is a key cardiovascular regulatory system involved in normal homeostasis and in disease pathophysiology. The activation of the RAS starts with the cleavage of angiotensinogen by renin to produce angiotensin I. Angiotensin I is then converted by the angiotensin converting enzyme (ACE) to generate angiotensin II (Ang II). In some tissues, Ang II may be formed by other enzymatic pathways including, for example, the heart chymase. 1À3 ACE is located on endothelial cells in the lungs and in many other vascular beds and on membranes of various cells. ACE is not a specific enzyme, since it uses bradykinin as a substrate in addition to angiotensin I. The low intraindividual, but high interindividual variability and the lack of association with environmental, metabolic and hormonal factors suggested that the plasma ACE level was genetically determined. 4 The ACE gene was mapped to chromosome 17q23. 5 Two different alleles can be identified by the presence (insertion, I) or the absence (deletion, D) of a 287-bp sequence in intron 16, resulting in three genotypes: II, ID and DD. The DD polymorphism is related to higher levels of plasma ACE. 6 Since the original report by Cambien et al. 7 of an association between the DD genotype and myocardial infarction, several studies have been performed in order to find an association between ACE gene polymorphisms and atherosclerosis in other vascular districts. Peripheral arterial occlusive disease (PAOD), myocardial infarction and ischaemic stroke share similar pathophysiology due to atherosclerosis, although it is not entirely clear that the latter is identical in all the arterial beds. 8 We determined the frequency of the insertion=deletion polymorphism in a cross-sectional study of patients admitted to our clinic with intermittent claudication, who subsequently were found, by angiography, to have lower extremity arterial occlusive disease.
Patients and methods
White adult Greeks from northern Greece were studied. Blood samples for DNA were collected from 100 patients admitted to the hospital with intermittent claudication, rest pain or gangrene (Fontaine classification II, III, IV, respectively) and from an age-matched control population. Control subjects were recruited from spouses and relatives of patients attending the hypertension outpatient clinic. A complete medical history, a physical examination and an a Second Propedeutic Department of Internal Medicine and b E' Surgical Clinic, Aristotle University of Thessaloniki, Hippokration Hospital, Greece ankleÀbrachial index (ABI) were undertaken for all individuals and blood samples were drawn for routine biochemical tests, especially for lipid profile. The presence or absence of hypertension, diabetes mellitus, hyperlipidaemia, cigarette smoking, coronary heart disease and previous stroke was carefully investigated (Tables 1 and 2).
Hypertension was defined as clinical systolic blood pressure !140 mmHg and=or diastolic blood pressure ! 90 mmHg in three measurements taken by mercury sphygmomanometer at 1-week intervals or by the presence of antihypertensive drugs. Diabetes mellitus was defined as fasting plasma glucose >126 mg=dl on two occasions. Hyperlipidaemia was defined as total cholesterol > 200 mg=dl and high-density lipoprotein cholesterol < 40 mg=dl for men and < 50 mg=dl for women. Coronary heart disease was defined as a history of Q or non-Q myocardial infarction or percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). Stroke was defined as a history of hospitalization for a syndrome of rapidly developing clinical signs of focal or global disturbance lasting for 24 hours or longer, attributed to ischaemic or haemorrhagic lesions in the brain and verified with CT scan or MRI. Individuals classified as smokers included those who had been ex-smokers. Control subjects were normotensive, they did not have diabetes mellitus, coronary heart disease or previous stroke and their ABI was !1.1. In all patients the ABI was < 0.8 and an angiography was performed in order to estimate the grade of occlusive disease of the lower extremity arteries. Patients and controls were divided into the three genotypes (II, ID and DD) depending on the result of their ACE genotyping.
Genomic DNA was extracted from blood samples by a modified salting-out method. Buffy coats of nucleated cells obtained from 10 ml of anticoagulated blood samples were resuspended in 10 ml lysis buffer I (0.3 mol=l sucrose, 10 mmol=l Tris-HCl, 5 mmol=l MgCl, 1% Triton X-100, pH 7.5). After centrifugation the pellets were dissolved in 4.5 lysis buffer II (75 mmol=l NaCl, 24 mmol=l Na-EDTA, pH 8.0), 125ml 10% sodium dodecyl sulfate (SDS) and 1.1 ml 5 mmol=l sodium perchlorate. Saturated NaCl (2 ml) was then added and shaken vigorously. Following centrifugation, the supernatant was ethanol precipitated. Polymerase chain reaction (PCR) was performed using primers that flank the I=D region in intron 16 of the ACE gene, as described before. 9 DMSO was also added to the PCR reaction to a final concentration of 5%. PCR samples were separated electrophoretically on 1.8% agarose gels and DNA was visualized by ethidium bromide staining. Samples identified with a DD genotype were additionally amplified with a set of primers flanking only the insertion allele, as performed by Shanmugan et al 10 to avoid mistyping of heterozygotes.
Statistical analysis
A possible association between ACE genotype and PAOD was investigated using a v 2 -test as a 3 Â 2 factorial of ACE genotype versus the presence or absence of occlusive disease. The odds ratio for the DD genotype versus other genotype was calculated along with the corresponding approximate 95% confidence interval. The multivariate regression analysis, stepwise method, was used for the possible correlation of all risk factors listed in Table 1 and the occurrence of PAOD. The chi-squared test was used for the determination of possible difference for the common risk factors in the two groups. Significance was defined as p < 0.05.
Results
The patient numbers recruited in the PAOD group were 13=58=29 and in the control group 17=48=35 for II=ID=DD genotypes, respectively. Allele frequencies for D and I alleles were 0.58 and 0.42 in patients and 0.59 and 0.41 in controls, respectively (Table 3) . No statistically significant difference could be found between the PAOD 
Discussion
This study was designed to determine the relationship between ACE gene insertion=deletion polymorphism and PAOD. Recent genetic studies have shown that a deletion polymorphism in the ACE gene may be a potent risk factor for myocardial infarction in humans. 7 However, results from coronary heart disease studies should not be extrapolated to PAOD, due to their partly different etiology. This ACE I=D polymorphism appears to be a major determinant of circulating and tissue ACE with serum levels of ACE being higher in subjects homozygous for the D allele. 6 The potential clinical significance is suggested by several studies which have demonstrated that ACE inhibitors reduce the rate of recurrence of myocardial infarction in patients with left ventricular dysfunction. 11À13 In the ELITE II study, the comparison of losartan with captopril in patients with heart failure showed that losartan also may have cardioprotective value. 14 These data are consistent with the hypothesis that the blockade of the reninangiotensin system may alter the natural history of human coronary atherosclerosis. ACE exists as both a circulating enzyme and a cell membrane-associated ectoenzyme. Plasma levels represent a small fraction of the total-body ACE content, which is mostly present on tissue endothelial cells throughout the body and in the parenchymal cells of certain tissues. Many studies confirm the expression of ACE in atherosclerotic lesions, smooth muscle cells, macrophages and fibroblasts. 15 The expression of vascular ACE in atherosclerotic lesions has been confirmed in hypercholesterolemic rabbits 16, 17 and in humans. 15 In rabbits, the increase in ACE expression preceded lesion development, providing support for the hypothesis that ACE may play a role in the initiation of the lesion. In addition to its proatherogenic actions via the production of angiotensin II, ACE may also participate in the initiation and progression of atherosclerosis by a second mechanism, i.e. decreases in nitric oxide (NO) production. ACE degrades bradykinin, a potent inducer of NO release, which in addition to its vasodilatory actions has several antiatherogenic effects. 18, 19 Therefore, ACE may participate in atherogenesis by activation of a proatherogenic pathway (Ang II) and inhibition of an antiatherogenic pathway (NO).
Ang II has been implicated in the pathobiology of atherosclerosis via mechanisms that include vascular hypertrophy, extracellular matrix production and induction of cytokines, secreted from leukocytes and smooth muscle cells. 20 It has been demonstrated that both immunoreactive Ang II and ACE may be found within the walls of atherosclerotic coronary arteries. 21, 22 The uptake of LDL-cholesterol by the vessel wall, with subsequent oxidation and uptake by macrophages, is central to the development of atherosclerotic lesions. It has been shown that infusion of Ang II into rabbits or rats increases the vascular uptake of LDL. 23, 24 Marked reductions in aortic atherosclerosis have been demonstrated after treatment of Watanabe heritable hyperlipidemic rabbits with ACE inhibitors. These animals have a genetic defect in the low-density lipoprotein (LDL) receptor, which causes elevations in circulating LOL and early onset of atherosclerosis. 25, 26 The above action was not dependent on the reduction in blood pressure because other antihypertensive drugs failed to influence lesion characteristics in this animal model. Antiatherosclerotic effects of ACE inhibition were also reported in several other animal models. 27À30 In animal models of atherosclerosis, blockade of the Ang II type I receptor inhibits monocyte activation, 31 LDL oxidation, 32 and fatty streak formation. 33 It has also been reported that ACE is associated with inflammatory areas and areas of neovascularization within human carotid atheromatous plaques. This might provide a mechanism for increased contributions of angiotensin II to atherosclerotic progression and vascular remodeling. 34 Several studies have suggested a weak or no significant association between the ACE gene and ischaemic stroke, 35, 36 renovascular hypertension, 37,38 carotid wall thickening, 39,40 hypertension 41 and left ventricular hypertrophy independent of blood pressure. 42 There are only two published studies investigating the relation of ACE polymorphism with PAOD. In the first study, including 98 patients, Taute et al did not find a link between the deletion allele and the manifestation of PAOD. 43 In the second one, including 522 patients, Renner et al concluded that the ACE I=D polymorphism is not a risk factor for PAOD. 44 Our results demonstrate an absence of association between DD genotype and PAOD. However, larger studies in different ethnic groups are needed for a complete understanding of the relationship between the ACE genotype and PAOD.
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